Dextroamphetamine - Pharmacology
Research News and Information

Saturday, November 21, 2009

Behavioural and dopaminergic alterations induced by a low dose of WIN 55,212-2 in a conditioned place preference procedure.

5 Jun 2009 AIMS: This study investigated the role of the cannabinoid CB1 receptor agonist, WIN 55,212-2, on motor activity. Subsequently, the effects of a low, stimulatory dose of WIN 55,212-2 and cocaine, as a positive control, were evaluated using a ... Read more...

Effects of the cannabinoid receptor ligands on anxiety-related effects of d-amphetamine and nicotine in the mouse elevated plus maze test.

30 May 2009 The purpose of the experiments was to examine the anxiety-related effects of d-amphetamine and nicotine, and the possible involvement of the endocannabinoid system. D-amphetamine (2 mg/kg, ip) was administered acutely or daily for 8 days. On the 9th ... Read more...

A novel operant conflict procedure using incrementing shock intensities to assess the anxiolytic and anxiogenic effects of drugs.

29 Apr 2009 There is a need for novel anxiolytics, which are effective, but do not cause sedation, tolerance, and rebound anxiety on discontinuation. To investigate a procedure that can be used to assess these characteristics preclinically, rats were initially ... Read more...

Latest indexed articles for 'Dextroamphetamine - Pharmacology'

These are the very latest articles for this heading:

• Behavioural and dopaminergic alterations induced by a low dose of WIN 55,212-2 in a conditioned place preference procedure. 5 Jun 2009
• Effects of the cannabinoid receptor ligands on anxiety-related effects of d-amphetamine and nicotine in the mouse elevated plus maze test. 30 May 2009
• A novel operant conflict procedure using incrementing shock intensities to assess the anxiolytic and anxiogenic effects of drugs. 29 Apr 2009
• The GABA-B antagonist 2-hydroxysaclofen reverses the effects of baclofen on the discriminative stimulus effects of D-amphetamine in the conditioned taste aversion procedure. 6 Apr 2009
• Community structure in networks of functional connectivity: resolving functional organization in the rat brain with pharmacological MRI. 31 Mar 2009
• Effects of co-administration of bupropion and nicotine or D-amphetamine on the elevated plus maze test in mice. 30 Mar 2009
• Dopamine modulates effort-based decision making in rats. 30 Mar 2009
• Studies of the biogenic amine transporters. 13. Identification of "agonist" and "antagonist" allosteric modulators of amphetamine-induced dopamine release. 22 Feb 2009
• Phosphodiesterase 10A inhibition modulates the sensitivity of the mesolimbic dopaminergic system to D-amphetamine: involvement of the D1-regulated feedback control of midbrain dopamine neurons. 17 Feb 2009
• How to keep the brain awake? The complex molecular pharmacogenetics of wake promotion. 2 Feb 2009
• Specificity of direct transition from wake to REM sleep in orexin/ataxin-3 transgenic narcoleptic mice. Feb 2009
• Schizophrenia model of elevated D2(High) receptors: haloperidol reverses the amphetamine-induced elevation in dopamine D2(High). 23 Jan 2009
• Effects of d-amphetamine on behavior maintained by signaled and unsignaled delays to reinforcement. 20 Jan 2009
• Rapid acquisition of preference in concurrent schedules: effects of d-amphetamine on sensitivity to reinforcement amount. 15 Jan 2009
• Timing and space usage are disrupted by amphetamine in rats maintained on DRL 24-s and DRL 72-s schedules of reinforcement. 12 Jan 2009
• Lisdexamfetamine dimesylate: in attention-deficit hyperactivity disorder in adults. 30 Dec 2008
• Discriminative-stimulus and time-course effects of kava-kava (Piper methysticum) in rats. 29 Dec 2008
• Amphetamine-induced place preference in humans. 23 Dec 2008
• Discriminative stimulus and subject-rated effects of methamphetamine, d-amphetamine, methylphenidate, and triazolam in methamphetamine-trained humans. 20 Dec 2008
• Differential alterations in the relations among GABAergic, catecholaminergic and calcium binding protein expression in the olfactory bulb of amphetamine-administered mouse. 17 Nov 2008

See a longer list of these articles.

Technical information about 'Dextroamphetamine'

Definition: The d-form of AMPHETAMINE. It is a central nervous system stimulant and a sympathomimetic. It has also been used in the treatment of narcolepsy and of attention deficit disorders and hyperactivity in children. Dextroamphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulating release of monamines, and inhibiting monoamine oxidase. It is also a drug of abuse and a psychotomimetic.

Chemical name: Benzeneethanamine, alpha-methyl-, (S)-

Registry Number: 51-64-9

Descriptor UI: D003913

Alternative terms: Dextroamphetamine; dextro-Amphetamine; dextro Amphetamine; Dexamphetamine; d-Amphetamine; d Amphetamine; Dexamfetamine; Oxydess; Vortech Brand of Dextroamphetamine Sulfate; Dextroamphetamine Sulfate; Sulfate, Dextroamphetamine; d-Amphetamine Sulfate; d Amphetamine Sulfate; Dextro-Amphetamine Sulfate; Dextro Amphetamine Sulfate; DextroStat; Shire Brand of Dextroamphetamine Sulfate; Curban; Pasadena Brand of Dextroamphetamine; Dexedrine; GlaxoSmithKline Brand of Dextroamphetamine Sulfate; Mallinckrodt Brand of Dextroamphetamine Sulfate; Celltech Brand of Dextroamphetamine Sulfate;

Allowable Qualifiers: administration & dosage; adverse effects; analogs & derivatives; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Pharmacological Action: Dopamine Uptake Inhibitors; Central Nervous System Stimulants;

Tree Number: D02.092.471.683.152.110.200;

Online Note: use DEXTROAMPHETAMINE to search DEXTRO AMPHETAMINE 1966-76

History Note: 77; was DEXTRO AMPHETAMINE 1963-76